Skip to content
Technology
Pipeline
News
People
Partners
Careers
Contact
Menu
Technology
Pipeline
News
People
Partners
Careers
Contact
EA-2353 has the potential to reverse the loss of vision in patients with Retinitis Pigmentosa
Prev
Previous
Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye
Next
Michael Lai joins Endogena as Medical Director
Next
